Global Information
회사소개 | 문의 | 비교리스트

개방각녹내장(OAG) : 역학 예측(-2030년)

Open-Angle Glaucoma - Epidemiology Forecast to 2030

리서치사 DelveInsight Business Research LLP
발행일 2020년 04월 상품 코드 534932
페이지 정보 영문 100 Pages
가격
US $ 3,750 ₩ 4,660,000 PDF by E-mail (Single User License)
US $ 7,500 ₩ 9,321,000 PDF by E-mail (Site License)
US $ 11,250 ₩ 13,982,000 PDF by E-mail (Global License)


개방각녹내장(OAG) : 역학 예측(-2030년) Open-Angle Glaucoma - Epidemiology Forecast to 2030
발행일 : 2020년 04월 페이지 정보 : 영문 100 Pages

주요 7개국(미국, 영국, 독일, 프랑스, 이탈리아, 스페인, 일본)의 개방각녹내장(OAG) 시장을 조사했으며, 질병 개요 및 국가별 역학, 병형·임상 증상별 유병 수의 추이와 예측을 정리하여 전해드립니다.

목차

제1장 주요 인사이트

제2장 개방각녹내장(OAG) 시장의 개요

  • 개방각녹내장(OAG)의 시장 점유율(실적)
  • 개방각녹내장(OAG)의 시장 점유율(예측)

제3장 질병 배경과 개요 : 개방각녹내장(OAG)

  • 서론
  • 분류
  • 징후와 증상
  • 위험인자
  • 임상 증상
  • 유전적 기반
    • 마이오실린(MYOC, OMIM #601652)
    • 옵티뉴린(OPTN, OMIM #602432)
    • TANK 결합 키나아제-1(TANK-binding Kinase-1)
    • WD 리피트 36(WDR36, OMIM 609669)
  • 진단

제4장 역학과 환자 인구

  • 주요 조사 결과
  • 주요 7개국의 개방각녹내장(OAG) 총유병 수
  • 주요 7개국의 개방각녹내장(OAG) 진단 수

제5장 미국 개방각녹내장(OAG)의 역학

  • 개방각녹내장(OAG)의 총유병 수
  • 개방각녹내장(OAG)의 진단 수
  • 개방각녹내장(OAG)의 유병 수 : 성별
  • 개방각녹내장(OAG)의 유병 수 : 연령별
  • 개방각녹내장(OAG)의 유병 수 : 병형별

제6장 EU 5개국 개방각녹내장(OAG)의 역학

  • 독일
    • 개방각녹내장(OAG)의 총유병 수
    • 개방각녹내장(OAG)의 진단 수
    • 개방각녹내장(OAG)의 유병 수 : 성별
    • 개방각녹내장(OAG)의 유병 수 : 연령별
    • 개방각녹내장(OAG)의 유병 수 : 병형별
  • 프랑스
    • 개방각녹내장(OAG)의 총유병 수
    • 개방각녹내장(OAG)의 진단 수
    • 개방각녹내장(OAG)의 유병 수 : 성별
    • 개방각녹내장(OAG)의 유병 수 : 연령별
    • 개방각녹내장(OAG)의 유병 수 : 병형별
  • 이탈리아
    • 개방각녹내장(OAG)의 총유병 수
    • 개방각녹내장(OAG)의 진단 수
    • 개방각녹내장(OAG)의 유병 수 : 성별
    • 개방각녹내장(OAG)의 유병 수 : 연령별
    • 개방각녹내장(OAG)의 유병 수 : 병형별
  • 스페인
    • 개방각녹내장(OAG)의 총유병 수
    • 개방각녹내장(OAG)의 진단 수
    • 개방각녹내장(OAG)의 유병 수 : 성별
    • 개방각녹내장(OAG)의 유병 수 : 연령별
    • 개방각녹내장(OAG)의 유병 수 : 병형별
  • 영국
    • 개방각녹내장(OAG)의 총유병 수
    • 개방각녹내장(OAG)의 진단 수
    • 개방각녹내장(OAG)의 유병 수 : 성별
    • 개방각녹내장(OAG)의 유병 수 : 연령별
    • 개방각녹내장(OAG)의 유병 수 : 병형별

제7장 일본 개방각녹내장(OAG)의 역학

  • 개방각녹내장(OAG)의 총유병 수
  • 개방각녹내장(OAG)의 진단 수
  • 개방각녹내장(OAG)의 유병 수 : 성별
  • 개방각녹내장(OAG)의 유병 수 : 연령별
  • 개방각녹내장(OAG)의 유병 수 : 병형별

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

KSA 19.11.08

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Table 1 Summary of OAG Epidemiology and Key Events (2017-2030)
  • Table 2 Clinical Stages of Primary Open-Angle Glaucoma
  • Table 3 Two Classes of Primary Open-Angle Glaucoma (POAG) Mutations
  • Table 4 Genes associated with the risk of POAG
  • Table 5 Innate and adaptive immunity changes in POAG
  • Table 6 The definitions and levels of evidence to rate individual studies
  • Table 7 Recommendations for care are formed based on the body of the evidence. The body of evidence quality ratings are defined by GRADE
  • Table 8 Primary Open-Angle Glaucoma Preferred Practice Pattern guidelines
  • Table 9 Total Prevalence of Glaucoma in the 7MM (2017-2030)
  • Table 10 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the 7MM (2017-2030)
  • Table 11 Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM (2017-2030)
  • Table 12 Total Prevalence of Glaucoma in the United States (2017-2030)
  • Table 13 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the US (2017-2030)
  • Table 14 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the US (2017-2030)
  • Table 15 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States(2017-2030)
  • Table 16 Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States (2017-2030)
  • Table 17 Total Prevalence of Glaucoma in Germany (2017-2030)
  • Table 18 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Germany (2017-2030)
  • Table 19 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany (2017-2030)
  • Table 20 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany (2017-2030)
  • Table 21 Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany (2017-2030)
  • Table 22 Total Prevalence of Glaucoma in France (2017-2030)
  • Table 23 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in France (2017-2030)
  • Table 24 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in France (2017-2030)
  • Table 25 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in France (2017-2030)
  • Table 26 Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in France (2017-2030)
  • Table 27 Total Prevalence of Glaucoma in Italy (2017-2030)
  • Table 28 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Italy (2017-2030)
  • Table 29 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy (2017-2030)
  • Table 30 Age-specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy (2017-2030)
  • Table 31 Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy (2017-2030)
  • Table 32 Total Prevalence of Glaucoma in Spain (2017-2030)
  • Table 33 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Spain (2017-2030)
  • Table 34 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain (2017-2030)
  • Table 35 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain (2017-2030)
  • Table 36 Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain (2017-2030)
  • Table 37 Total Prevalence of Glaucoma in the United Kingdom (2017-2030)
  • Table 38 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the United Kingdom (2017-2030)
  • Table 39 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom (2017-2030)
  • Table 40 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom (2017-2030)
  • Table 41 Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom (2017-2030)
  • Table 42 Total Prevalence of Glaucoma in Japan (2017-2030)
  • Table 43 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Japan (2017-2030)
  • Table 44 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2017-2030)
  • Table 45 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2017-2030)
  • Table 46 Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2017-2030)

List of Figures

  • Figure 1 Aqueous humor production and flow
  • Figure 2 Development of Glaucoma
  • Figure 3 Classification of Open-Angle Glaucoma
  • Figure 4 Symptoms of Open-Angle Glaucoma
  • Figure 5 Risk Factors Associated with POAG
  • Figure 6 Factors Contributing to the Pathophysiology of Glaucomatous Neurodegeneration
  • Figure 7 Pathophysiology of Primary Open-Angle Glaucoma
  • Figure 8 Proposed pathways for normal secretion of myocilin into the aqueous humor and for secretion reduced by a MYOC mutation
  • Figure 9 Diagnosis of Primary Open-Angle Glaucoma (POAG)
  • Figure 10 Glaucoma Assessment (Optic Nerve)
  • Figure 11 Total Prevalence of Glaucoma in the 7MM (2017-2030)
  • Figure 12 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the 7MM (2017-2030)
  • Figure 13 Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM (2017-2030)
  • Figure 14 Total Prevalence of Glaucoma in the United States (2017-2030)
  • Figure 15 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the US (2017-2030)
  • Figure 16 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the US (2017-2030)
  • Figure 17 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States (2017-2030)
  • Figure 18 Type-Specific Diagnosed Prevalence of OAG in the United States (2017-2030)
  • Figure 19 Total Prevalence of Glaucoma in Germany (2017-2030)
  • Figure 20 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Germany (2017-2030)
  • Figure 21 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany (2017-2030)
  • Figure 22 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany (2017-2030)
  • Figure 23 Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany (2017-2030)
  • Figure 24 Total Prevalence of Glaucoma in France (2017-2030)
  • Figure 25 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in France (2017-2030)
  • Figure 26 Gender-specific Diagnosed Prevalence of Open-Angle Glaucoma in France (2017-2030)
  • Figure 27 Age-specific Diagnosed Prevalence of Open-Angle Glaucoma in France (2017-2030)
  • Figure 28 Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in France (2017-2030)
  • Figure 29 Total Prevalence of Glaucoma in Italy (2017-2030)
  • Figure 30 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Italy (2017-2030)
  • Figure 31 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy (2017-2030)
  • Figure 32 Age-specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy (2017-2030)
  • Figure 33 Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy (2017-2030)
  • Figure 34 Total Prevalence of Glaucoma in Spain (2017-2030)
  • Figure 35 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Spain (2017-2030)
  • Figure 36 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain (2017-2030)
  • Figure 37 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain (2017-2030)
  • Figure 38 Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain (2017-2030)
  • Figure 39 Total Prevalence of Glaucoma in the United Kingdom (2017-2030)
  • Figure 40 Total Diagnosed Prevalent Population of OAG in the United Kingdom (2017-2030)
  • Figure 41 Gender-Specific Diagnosed Prevalence of OAG in the United Kingdom (2017-2030)
  • Figure 42 Age-Specific Diagnosed Prevalence of OAG in the United Kingdom (2017-2030)
  • Figure 43 Type-Specific Diagnosed Prevalence of OAG in the United Kingdom (2017-2030)
  • Figure 44 Total Prevalence of Glaucoma in Japan (2017-2030)
  • Figure 45 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Japan (2017-2030)
  • Figure 46 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2017-2030)
  • Figure 47 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2017-2030)
  • Figure 48 Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2017-2030)

DelveInsight's Open-angle glaucoma (OAG)-Epidemiology Forecast-2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of OAG in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Open-angle glaucoma (OAG) - Disease Understanding

Open-angle glaucoma (OAG) is a progressive form of glaucoma in which the channel formed between the iris and the cornea remains open and tissue changes along the channel, which gradually reduces the drainage of the aqueous humor through the trabecular meshwork of the eye's anterior chamber. It is the most common form of glaucoma which accounts for the majority of the glaucoma cases. The term "Open-Angle" refers to the angle where the iris meets the cornea and is as wide and open as it should be. OAG is mainly caused by the slow clogging of the drainage canals, resulting in increased eye pressure.

The OAG is primarily divided into two subtypes, i.e., Primary OAG and Secondary OAG. The risk factors of open-angle glaucoma are divided into four categories, general factors, ocular factors, nonocular factors, and ocular hypertension.

Open-angle glaucoma (OAG) - Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Prevalence of Glaucoma in the 7MM, Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the 7MM, Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM, Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM and Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM scenario of OAG in the 7MM countries covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.

As per DelveInsight's analysis, a higher percentage of diagnosed prevalence of OAG was observed for females, in comparison to males, in all the 7MM countries. DelveInsight's analysts have assessed that the total prevalent population of Glaucoma in the 7MM was 9,819,080 in 2017. In addition to this it was also assessed that among those with glaucoma in the 7MM, more than 8.5 million were diagnosed with OAG. DelveInsight's estimate suggests that the United States witnessed the highest number of cases with OAG, as compared to other 7MM countries. As per DelveInsight's estimates, the country accounted for approximately 2,749,378 cases in 2017.

Among the EU-5 countries, Germany accounted for the highest number of glaucoma cases in 2017, which was observed to be equivalent to more than 25% of the total affected population in this region. The number of cases for glaucoma was observed to be 1,041,889 in the country for 2017. However, Spain accounted for the lowest number of glaucoma cases in 2017, which was approximately 13.33% of the total affected population of EU-5 countries. According to DelveInsight's analysts, Japan accounted for the second-highest number of OAG patients, i.e., 28.79% of the total OAG population in the 7MM countries.

According to DelveInsight's assessment, it has been observed that OAG prevalence varied across the 7MM countries, based on the age-specific prevalence of the disease. For instance, the highest proportion was observed in the 70-79 years age group in the US, while in the EU-5 countries, people aged ≥80 years accounted for the maximum patient pool. In contrast, the middle age population aged 50-59 years contributed to the highest patient pool in Japan.

Report Scope:

  • The report covers a detailed overview of Open-angle glaucoma explaining its causes, symptoms, classification, pathophysiology, and diagnosis.
  • The report provides insight into the historical and forecasted patient pool for seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Open-angle glaucoma
  • The report helps to recognize the growth opportunities in the 7MM countries with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology by total Prevalence of Glaucoma in the 7MM, Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the 7MM, Gender-Specific Diagnosed Prevalence in the 7MM, Age-Specific Diagnosed Prevalence in the 7MM, and Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM.

Open-angle glaucoma Report Key Strengths

  • 11 Year Forecast
  • 7MM Coverage
  • Total Prevalence of Glaucoma
  • Total Diagnosed Prevalent Population of Open-Angle Glaucoma
  • Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma
  • Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma
  • Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma

Open-angle glaucoma Report Assessment

  • Patient segmentation
  • Disease risk and burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary of Open-Angle Glaucoma

3. Open-Angle Glaucoma (OAG): Epidemiology Overview at a Glance

  • 3.1. Total Prevalent Cases of OAG in 2017
  • 3.2. Total Prevalent Cases of OAG in 2030

4. Open-Angle Glaucoma: Disease Background and Overview

  • 4.1. Introduction
  • 4.2. Classification of Open-Angle Glaucoma
  • 4.3. Signs and Symptoms of Open-Angle Glaucoma
  • 4.4. Risk Factors of Primary Open-Angle Glaucoma (POAG)
    • 4.4.1. General
    • 4.4.2. Ocular
    • 4.4.3. Nonocular
    • 4.4.4. Ocular Hypertension
  • 4.5. Pathophysiology of Primary Open-Angle Glaucoma (POAG)
  • 4.6. Genes Involved in Primary Open-Angle Glaucoma
    • 4.6.1. Myocilin
    • 4.6.2. Optineurin
    • 4.6.3. TANK-binding Kinase-1 (TBK1)
    • 4.6.4. WD-repeat domain 36 (WDR36, OMIM 609669)
  • 4.7. Biomarkers associated with Primary Open Angle Glaucoma (POAG)
  • 4.8. Diagnosis of Open-Angle Glaucoma
    • 4.8.1. Diagnosis of Primary Open-Angle Glaucoma
    • 4.8.2. Primary Open-Angle Glaucoma Preferred Practice Pattern guidelines

5. Case Reports

  • 5.1. Managing Juvenile Open-Angle Glaucoma
  • 5.2. Visual improvement following glaucoma surgery: a case report
  • 5.3. Evidence-based medicine in glaucoma surgery

6. Epidemiology and Patient Population

  • 6.1. Key Findings
  • 6.2. Epidemiology Methodology
  • 6.3. Total Prevalence of Glaucoma in the 7MM
  • 6.4. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the 7MM
  • 6.5. Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM

7. United States Epidemiology

  • 7.1. Assumptions and Rationale
  • 7.2. Total Prevalence of Glaucoma in the United States
  • 7.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the United States
  • 7.4. Gender- Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States
  • 7.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States
  • 7.6. Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States

8. EU5 Epidemiology

  • 8.1. Germany Epidemiology
    • 8.1.1. Assumptions and Rationale
    • 8.1.2. Total Prevalence of Glaucoma in Germany
    • 8.1.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Germany
    • 8.1.4. Gender- Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany
    • 8.1.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany
    • 8.1.6. Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany
  • 8.2. France Epidemiology
    • 8.2.1. Assumptions and rationale
    • 8.2.2. Total Prevalence of Glaucoma in France
    • 8.2.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in France
    • 8.2.4. Gender-specific Diagnosed Prevalence of Open-Angle Glaucoma in France
    • 8.2.5. Age-specific Diagnosed Prevalence of Open-Angle Glaucoma in France
    • 8.2.6. Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in France
  • 8.3. Italy Epidemiology
    • 8.3.1. Assumptions and Rationale
    • 8.3.2. Total Prevalence of Glaucoma in Italy
    • 8.3.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Italy
    • 8.3.4. Gender-specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy
    • 8.3.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy
    • 8.3.6. Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy
  • 8.4. Spain Epidemiology
    • 8.4.1. Assumptions and Rationale
    • 8.4.2. Total Prevalence of Glaucoma in Spain
    • 8.4.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Spain
    • 8.4.4. Gender- Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain
    • 8.4.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain
    • 8.4.6. Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain
  • 8.5. United Kingdom Epidemiology
    • 8.5.1. Assumptions and Rationale
    • 8.5.2. Total Prevalence of Glaucoma in the United Kingdom
    • 8.5.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the United Kingdom
    • 8.5.4. Gender- Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom
    • 8.5.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom
    • 8.5.6. Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom

9. Japan Epidemiology

  • 9.1. Assumptions and Rationale
  • 9.2. Total Prevalence of Glaucoma in Japan
  • 9.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Japan
  • 9.4. Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan
  • 9.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan
  • 9.6. Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan

10. Appendix

  • 10.1. Report Methodology

11. DelveInsight Capabilities

12. Disclaimer

13. About DelveInsight

Back to Top
전화 문의
F A Q